J. Goldman & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

J. Goldman & Co’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-80,000	Closed	-$9.29M	–	307
2013 Q3	$9.29M	Buy	+80,000	New	+$8.78M	0.87%	22

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

J. Goldman & Co's ALXN Position: Q1 2017 in Review

J. Goldman & Co sold out of Alexion Pharmaceuticals (ALXN) in Q1 2017, closing a stake of 4,600 shares — an estimated $563K sold.

J. Goldman & Co first reported a position in ALXN in Q4 2016 and held it in 1 quarter. The position peaked at $563K in Q4 2016. 561 funds tracked by Wall St. Rank hold ALXN as of Q1 2017.

J. Goldman & Co reported no remaining Alexion Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
J. Goldman & Co sold 4,600 Alexion Pharmaceuticals shares in Q1 2017, an estimated $563K.
J. Goldman & Co first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 1 quarter.
J. Goldman & Co's Alexion Pharmaceuticals position peaked at $563K in Q4 2016.
561 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2017.

Based on J. Goldman & Co's 13F filing for Q1 2017, filed 15 May 2017.